Abstract: The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.
Abstract: A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.
Type:
Grant
Filed:
August 5, 2009
Date of Patent:
February 18, 2014
Assignees:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary of the Army, U.S.A., The United States of America, as represented by the Secretary of the Department of Health and Human Services
Inventors:
Wesley M. Jackson, Leon J. Nesti, Rocky S. Tuan
Abstract: The present invention deals with a method for therapeutic or prophylactic treatment of HIV, in particular a prophylactic vaccinal method, comprising at least: administering to a patient a first antigen comprising the broadly neutralizing epitopes of the Membrane Proximal Ectodomain Region (MPER) of gp41, and administering to the same patient a second antigen comprising a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising: a N-helix region of gp41(N), a C-helix region of gp41(C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2.
Abstract: A cancer vaccine containing as an active ingredient an antigen-specific dendritic cell pulsed by an HM1.24 protein, HM1.24 peptide or transduced with an HM1.24-encoding gene, or HM1.24 protein-encoding DNA or RNA.
Type:
Grant
Filed:
October 30, 2003
Date of Patent:
February 18, 2014
Assignees:
Chugai Seiyaku Kabushiki Kaisha, University College London
Abstract: Methods and apparatus for a free-standing biodegradable patch suitable for medical applications, especially intravascular, minimally-invasive and intraoperative surgical applications are provided, wherein the patch comprises a free-standing film or device having a mixture of a solid fibrinogen component and a solid thrombin component that, when exposed to an aqueous environment, undergoes polymerization to form fibrin. In alternative embodiments the patch may comprise a solid fibrinogen component, with or without an inorganic calcium salt component. The patch may take a non-adherent form during delivery to a target location within a vessel or tissue, and thereafter may be activated to adhere to vessel wall or tissue, and may include a number of additives, including materials to improve the mechanical properties of the patch, or one or more therapeutic or contrast agents.
Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.
Type:
Grant
Filed:
February 13, 2013
Date of Patent:
February 11, 2014
Assignee:
Loma Linda University
Inventors:
David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
Abstract: A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and collecting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.
Type:
Grant
Filed:
December 24, 2009
Date of Patent:
February 11, 2014
Assignee:
The Chemo-Sero-Therapeutic Research Institute
Abstract: A method and composition for treating cancer comprising administering to a patient an effective amount of attenuated Salmonella typhimurium containing a plasmid carrying the coding sequence encoding a truncated human interleukin-2 and optionally an oil containing a high antioxidant concentration.
Type:
Grant
Filed:
June 15, 2012
Date of Patent:
February 11, 2014
Assignee:
Cureium Therapeutics LLC
Inventors:
Arnold S. Leonard, Daniel A. Saltzman, Mark J. Mueller
Abstract: Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. The medical conditions may include wounds, mucositis among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
Abstract: The present invention relates to delivery systems. In particular, the present invention provides microporous scaffolds having thereon agents (e.g., extracellular matrix proteins, exendin-4) and biological material (e.g., pancreatic islet cells). In some embodiments, the scaffolds are used for transplanting biological material into a subject. In some embodiments, the scaffolds are used in the treatment of diseases (e.g., type 1 diabetes), and related methods (e.g., diagnostic methods, research methods, drug screening).
Abstract: Provided herein are compositions, devices and systems comprising thermoresponsive, biodegradable elastomeric materials, and methods of use and manufacture thereof.
Type:
Application
Filed:
January 31, 2012
Publication date:
February 6, 2014
Applicant:
NORTHWESTERN UNIVERSITY
Inventors:
Jian Yang, Robert Van Lith, Guillermo Ameer
Abstract: The invention provides methods and compositions suitable for preventing and treating hyperleptinemia, preventing and treating insulin resistance, preventing and treating cardiovascular disease, preventing and treating obesity, preventing and treating hyperlipidemia, and preventing and treating hypertension in an animal. The methods comprise administering one or more isoflavones to the animal, preferably in amounts of from about 0.001 to about 10 g/kg/day.
Abstract: A method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving dietary phosphorus absorption and retention, or for improving the efficacy of the phytase, or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure, which method comprising administering to a subject at least one direct fed microbial in combination with a phytase, wherein the phytase is administered to the subject at a dosage of more than about 1500 FTU/kg feed.
Type:
Application
Filed:
March 14, 2013
Publication date:
February 6, 2014
Inventors:
Luis Romero, Peter Plumstead, Luke Barnard
Abstract: The present invention is about conditioning compositions for hair comprising spray dried yoghurt powder and at least one cationic conditioning agent. With the compositions of the present invention hair properties such as smoothness, elasticity, volume and body and shine is improved. According to the present invention the yoghurt powder comprising compositions can be applied to hair as a shampoo, conditioner either leave in and/or rinse off types.
Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents.
Type:
Grant
Filed:
August 25, 2011
Date of Patent:
February 4, 2014
Assignee:
Stemnion, Inc.
Inventors:
Richard A. Banas, David L. Steed, Randall G. Rupp
Abstract: The present invention relates to amoebae (slime molds) and uses thereof. In particular, the present invention relates to the use of amoebae or their environmentally stable spores to treat microbial infections and other uses.
Type:
Application
Filed:
September 27, 2013
Publication date:
January 30, 2014
Applicant:
AMEBAGONE, LLC
Inventors:
Marcin Filutowicz, Katarzyna Dorota Borys
Abstract: The present invention relates to improved therapies for the treatment of heart disease, particularly the improved delivery of therapeutic agents to heart tissue by direct infusion into the coronary circulation. A preferred embodiment of the invention is a method comprising, identifying a mammal in need of treatment or prevention of heart disease, and supplying NO to the coronary circulation prior to, and/or during the infusion of a therapeutic polynucleotide into a blood vessel of the coronary circulation in vivo.
Abstract: An anti-obesity agent containing, as an active ingredient, a microorganism which belongs to the species Lactobacillus reuteri and is capable of producing lipases having the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5 or amino acid sequences having deletion, substitution or addition of one or more amino acids in the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5. The anti-obesity agent enables a patient to take a normal meal yet preventing the absorption of a fat into the body which is the primary cause of obesity.
Abstract: Compositions and methods for the treatment of asthma may be prepared by drilling a hole in a coconut, adding about 1/4 pound of brown sugar (piloncillo) to an inside of the coconut, plugging the hole, wrapping the coconut in plastic, and allowing the coconut water and its contents to ferment 12 inches underground for 40 days. The resulting composition may have anti-inflammatory properties that can treat inflammation and asthma in users.
Type:
Grant
Filed:
July 5, 2011
Date of Patent:
January 28, 2014
Inventors:
Javier Lizano, Jesus Flores, Alberto Ontiveros
Abstract: An anti-obesity agent containing, as an active ingredient, a microorganism which belongs to the species Lactobacillus reuteri and is capable of producing lipases having the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5 or amino acid sequences having deletion, substitution or addition of one or more amino acids in the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5. The anti-obesity agent enables a patient to take a normal meal yet preventing the absorption of a fat into the body which is the primary cause of obesity.
Abstract: The present invention provides a method for preparing chitosan solutions to allow regulating the conditions in which the chitosan solution will gel. The present invention also provides methods for using chitosan solutions as compositions and for using chitosan solutions in vitro and in vivo.
Type:
Application
Filed:
September 16, 2013
Publication date:
January 16, 2014
Applicant:
University of Virginia Patent Foundation
Inventors:
Cato T. Laurencin, Lakshmi Sreedharan Nair
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
Type:
Application
Filed:
July 15, 2013
Publication date:
January 16, 2014
Inventors:
Eugene T. Michal, Olof Mikael Trollsas, Shubhayu Basu
Abstract: The present invention relates to compositions and methods for the modulation of TN 17 responses. The invention provides compositions for the induction of TN 17 responses containing a TLR agonist and an apoptotic cell-associated agent or containing a microbe-infected apoptotic cell. The compositions of the present invention may also contain dendritic cells capable inducing TN 17 responses. In other embodiments, the invention provides compositions for the inhibition of TN 17 responses containing one or more blocking agents. Methods and compositions for the modulation of TN 17 responses and for the treatment of TN 17-associated diseases and for cancer are also provided.
Abstract: Methods for differentiating stem cells are disclosed herein. These methods can be used to generate neurons, including, but not limited to, dopaminergic neurons. The disclosed methods include culturing stem cells in the absence of fibroblast growth factor-2 to generate embryoid bodies and culturing the embryoid bodies in the presence of an effective amount of at least one of stromal cell-derived factor 1, pleiotrophin, insulin-like growth factor 2, and ephrin B1 on an extracellular matrix for a period of time sufficient to produce dopaminergic neuronal cells. The differentiated cells can be used to study pharmaceutical agents that affect dopaminergic neurons and can be used in the treatment of neurodegenerative disorders such as Parkinson's disease.
Type:
Grant
Filed:
November 18, 2009
Date of Patent:
January 14, 2014
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: Biomaterials, in particular bone foams, a process for preparing such materials as well as an applicator for applying the biomaterials directly to the patient's application site, and the use of a composition comprising water, a surfactant and a propellant in the preparation of a bone foam for the preparation of a calcium phosphate foam wherein the foam is obtainable by the mixture of at least two phases, a first phase comprising water and optionally a propellant, a second phase comprising one or more sources for calcium and/or phosphate, and wherein the foaming is performed during the mixture of the at least two phases to provide an improved calcium phosphate foam, process for the preparation of a calcium phosphate foam, use of a composition, solid state structure, calcium phosphate cement foam and bone foam applicator.
Type:
Application
Filed:
November 10, 2010
Publication date:
January 9, 2014
Applicant:
STRYKER TRAUMA GMBH
Inventors:
Hartwig Steckel, Maren Kuhli, Torben Christian Sörensen, Nils Reimers
Abstract: Six bacterial strains: Bacillus simplex strain 03WN13, Bacillus simplex strain 03WN23, Bacillus simplex strain 03WN25, Pseudomonas koreensis strain 10IL21, Pantoea agglomerans strain 10IL31, and Pseudomonas lini strain 13IL01, are superior antagonists of Phytophthora erythroseptica Pethybr., the causative agent of pink rot on potatoes. These bacterial strains are effective for suppression and control of pink rot on potatoes.
Type:
Grant
Filed:
September 24, 2010
Date of Patent:
January 7, 2014
Assignee:
The United States of America, as represented by the Secretary of Agriculture
Inventors:
David A. Schisler, Patricia J. Slininger, Tugba Adiyaman
Abstract: The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed.
Type:
Grant
Filed:
February 2, 2012
Date of Patent:
January 7, 2014
Assignee:
New York Medical College
Inventors:
Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: Exemplary embodiments disclosed herein include a microorganism that produces, secretes and injects recombinant antibodies into eukaryote cells said the described microorganisms can be used to prepare pharmaceutical compositions for the treatment of human or veterinary diseases.
Type:
Grant
Filed:
March 12, 2008
Date of Patent:
January 7, 2014
Assignee:
Consejo Superior de Investigaciones Cientificas
Inventors:
Luis Angel Fernandez Herrero, Ana Blanco Toribio
Abstract: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.
Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.
Type:
Grant
Filed:
October 27, 2010
Date of Patent:
December 31, 2013
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Joseph A. Murray, Eric V. Marietta, Susan H. Barton, Veena Taneja, Ashutosh Mangalam
Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are disclosed and claimed. In addition, methods, compositions, and kits for forming coronary vasculature including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed.
Abstract: In certain aspects, the present invention provides methods and compositions relating to a Pnmt-positive progenitor cell. In certain aspects, the present invention relates to methods for isolating and transplanting the subject progenitor cells, and methods for treating diseases such as myocardiac injuries and neurodegenerative disorders.
Abstract: There is provided a medicinal agent that is effective and highly safe for the prevention or alleviation of a peripheral nerve disorder that develops as a side effect occurring after the administration of an anti-cancer agent. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and to a prophylactic or alleviating agent for a peripheral nerve disorder that contains the extract as an active ingredient. The agent containing the extract as an active ingredient is used for a prophylactic or alleviating agent for a peripheral nerve disorder induced by an anti-cancer agent and is a highly safe and remarkably highly useful medicinal agent with few side effects.
Type:
Grant
Filed:
August 28, 2008
Date of Patent:
December 24, 2013
Assignees:
Kyushu University, National University Corporation, Nippon Zoki Pharmaceutical Co., Ltd
Abstract: The present invention provides an immunotherapeutic agent and immunotherapy allowing the extension of the survival time of patients with pancreatic cancer. The immunotherapy of the present invention is characterized by comprising the steps of culturing peripheral blood lymphocytes of a patient with pancreatic cancer by stimulating the lymphocytes with an anti-CD3 antibody and an anti-CD52 antibody, thereby to obtain an immunotherapeutic agent, and administering at least four infusions of the resultant immunotherapeutic agent to the same patient, wherein each of the infusions of the immunotherapeutic agent comprises at least 15×109 cells of activated lymphocytes, the percentage of CD3? CD56+ NK cells in the activated lymphocytes is at least 30%, and the administration of the immunotherapeutic agent is begun for the patient who is in at least one state of two or more particular immunocompromised states.
Abstract: The invention is directed to coated solid pharmaceutical preparations having a very thin coating in the nanometer range and a method for producing such preparations. The coated solid pharmaceutical preparation can be prepared by using atomic layer deposition (ALD).
Type:
Application
Filed:
March 1, 2012
Publication date:
December 19, 2013
Applicant:
MERCK PATENT GMBH
Inventors:
Lauri Lehtonen, Heike Bley, Luc Van Der Heyden
Abstract: A method is provided including selecting a patient suffering from a condition, administering cells to the patient selected from the group consisting of: progenitor cells and genetically-modified cells, applying an electrical current to a site of the patient in a vicinity of nervous tissue, and configuring the current to stimulate the nervous tissue. Other embodiments are also described.
Abstract: A method including positioning a delivery device at a location in a blood vessel; advancing the delivery device a distance into a wall of the blood vessel to a treatment site beyond an external elastic lamina of the blood vessel; and after advancing the delivery device, introducing a treatment agent including a cellular component through the delivery device. A composition including a treatment agent comprising a cellular component associated with a matrix material, wherein the composition is suitable for percutaneous delivery. Also an apparatus suitable for delivering a treatment agent. Also, a kit including a treatment agent.
Abstract: The invention provides methods of cultivating microalgae photoautotrophically outdoors to prepare concentrated microalgae products containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) docosahexaenoic acid, two long-chain polyunsaturated fatty acids found in fish oil that are very important for human and animal health. It also provides concentrated microalgae products containing EPA and DHA and purified lipid products containing EPA and DHA purified from microalgae.
Type:
Grant
Filed:
September 25, 2011
Date of Patent:
December 10, 2013
Assignee:
Parry Nutraceuticals, Division of E.I.D. Parry (India) Ltd
Inventors:
Swati Sebastian Thomas, Swaminathan Kumaravel
Abstract: The present invention provides a novel method of treatment for treating brain disorders that manifest oxidative stress by providing targeted populations of neurons with the ability to catabolize the acetylated amino acid derivative, N-acetylaspatic acid (NAA) and further supply extraphysiological levels of ATP to neurons via the targeted expression of the NAA catabolic enzyme aspartoacylase (ASPA) in neurons and astrocytes.
Type:
Application
Filed:
May 30, 2013
Publication date:
December 5, 2013
Applicant:
University of Medicine and Dentistry of New Jersey
Abstract: A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and/or dendritic cells to interrupt autoimmunity in a host. The method provides a Fc? receptor-specific complex or a complex which results in the co-crosslinking of Fc?-chains for treating the leukocytes and/or dendritic cells which are in turn used to elicit an autoimmune interruption response in a subject with an autoimmune disease. The Fc? receptor-specific complex and/or complex which results in the co-crosslinking of Fc?-chains is used to treat a biological sample comprising leukocytes and/or dendritic cells from a patient, and upon reintroducing said biological sample to the patient, the pre-treated dendritic cells illicit an autoimmune interruption response in vivo.
Type:
Grant
Filed:
January 16, 2007
Date of Patent:
December 3, 2013
Assignee:
Canadian Blood Services
Inventors:
Alan H. Lazarus, Vinayakumar Siragam, Davor Brinc, John Freedman, Andrew R. Crow, Seng Song
Abstract: The invention discloses an engineered oncolytic respiratory syncytial virus (RSV), NS1 gene deficient RSV, and its usage to treat breast cancer by killing cancer cells with in vitro and in vivo evidences.
Type:
Grant
Filed:
May 18, 2010
Date of Patent:
December 3, 2013
Inventors:
Weidong Zhang, Lixian Jiang, Calvin Cao
Abstract: The present invention relates to a microcapsule preparation product of alginate-chitosan acyl derivatives, which is produced by mixing microcapsules of alginate-chitosan acyl derivatives with an aqueous solution, wherein the biomicrocapsule structureconsists of two parts, a microcapsule membrane and an inner core; the microcapsule membrane is a polyelectrolyte composite hydrogel membrane formed by chitosan, alginates and chitosan acyl derivatives, and the inner core is an alginate liquid or a hydrogel environment containing cells.
Type:
Application
Filed:
November 28, 2011
Publication date:
November 28, 2013
Applicant:
Dalian Institute of Chemical Physics, Chinese Academy of Sciences
Abstract: The present invention provides an influenza B virus M gene with a modification of at least one nucleotide proximate to the N-terminus of the M gene, more specifically at any one of nucleotide positions 265 to 294 of the M gene. The present invention also provides an influenza B virus comprising the modified M gene, the use of the modified M gene for the preparation of a vaccine and methods for preparing the modified influenza virus.
Abstract: The subject invention pertains to methods and materials for enhancing microbial resistance in plants. Specifically exemplified herein are grapevines transformed with polynucleotides that express a peptide which confers antimicrobial activity.
Type:
Grant
Filed:
June 13, 2006
Date of Patent:
November 26, 2013
Assignee:
University of Florida Research Foundation, Inc.
Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.
Type:
Grant
Filed:
December 22, 2008
Date of Patent:
November 26, 2013
Assignee:
Universitat Zurich
Inventors:
Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
Abstract: Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines comprising these mycobacteria are provided. Further provided are methods of making a recombinant mycobacterium, methods of inducing an immune response in a mammal, methods of inhibiting IL-12 production in a mammal, and methods of stimulating IL-12 production in a mammal. Vaccine adjuvants are also provided, as are methods of inducing immunity to a target antigen in a mammal.
Type:
Grant
Filed:
March 10, 2008
Date of Patent:
November 26, 2013
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Inventors:
William R. Jacobs, Jr., Kari Sweeney, Dee Dao, Steven A. Porcelli, John Chan, Tsungda Hsu
Abstract: A formulation containing an active substance encapsulated within an exine shell of a naturally occurring spore, together with a protective additive which is also encapsulated within the exine shell.
Type:
Application
Filed:
June 26, 2013
Publication date:
November 21, 2013
Inventors:
Stephen Lawrence ATKIN, Stephen Thomas BECKETT, Alberto DIEGO-TABOADA, Grahame MACKENZIE
Abstract: Embodiments of the invention are based on the fermentation of bacteria to produce nano-cellulose in oxygen permeable tubular bioreactors. The resulting hydrogel non-hollow fiber can be stretched and dewatered to form strong, stiff yet flexible fiber. The fiber can be dehydrated by freeze drying or solvent exchange to form macroporous material and then optionally soaked with a solution of growth factors, anti-inflammatory drugs, and/or anitibacterial agents to provide a slow release drug delivery device in fiber form. The surface of the fiber is composed of nano-structured cellulose which promotes cell migration, tissue integration, and the healing process. BC fibers are not degraded in the human body and thus are well suited as reinforcement of implants and growing tissue. Uses for the BC fibers include surgical sutures, and reinforcing and promoting regeneration of damaged tissue or implants.